Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Intraocular drug delivery device and associated methods

A delivery device, technology for active agents, used in ophthalmology to address retinal detachment, increased cost of eye care services, endophthalmitis and other complications

Inactive Publication Date: 2011-04-20
UNIV OF UTAH RES FOUND
View PDF7 Cites 12 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

This injection is painful and can cause retinal detachment, endophthalmitis, and other complications
Additionally, these injections are typically performed by retinal surgeons, who make up only a small percentage of ophthalmologists, creating a bottleneck in eye care delivery and increasing costs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Intraocular drug delivery device and associated methods
  • Intraocular drug delivery device and associated methods
  • Intraocular drug delivery device and associated methods

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0048] Standard clear-corneal phacoemulsification was performed on 35 rabbits using intraocular lens (Acrysof SA60AT from Alcon) implants. At each surgery, an intraocular device containing the active agent was inserted into the lens capsule of each rabbit. Rabbits were divided into 4 groups according to the active agent of the intraocular device. The device is loaded with 5-15 mg of Avastin, Timolol, Brimonidine or Latanoprost. Groups were evaluated for stability of intraocular devices and lenses, cystic fibrosis, and healing of cataract wounds and anterior segments. Each eye subgroup was assessed weekly for inflammation for 4 weeks and removed at one month for histopathological assessment of capsule and CDR integrity.

Embodiment 2

[0050] The surgery and procedures described in Example 1 were repeated except that aqueous and vitreous taps were performed every two weeks and utilizing high pressure liquid chromatography (HPLC) and / or enzyme-linked immunosorbent assay (ELISA) Analyze drug concentration. In each drug group, half of the eyes were removed at one month and the other half at two months. This was accomplished by sacrificing the rabbit and enucleating the eye, immediately freezing the eye in liquid nitrogen to prevent perturbation and redistribution of the drug within the ocular tissue. Eyes were then dissected into 3 parts (aqueous humor, vitreous, and retina / choroid layers) to assess anatomic toxicity and tissue drug concentrations. Retrieve the intraocular device and assess the amount of remaining drug. Comparing the Distribution Profile of Intraocular Devices to Conventional Intravitreal Injection of 2.5 mg / 0.1cc Avastin distribution curves for direct comparison of different delivery metho...

Embodiment 3

[0053] Following lens extraction (phacoemulsification technique), three intraocular devices were implanted into eyes of New Zealand white rabbits under general anesthesia. Two devices were loaded with Avastin and one device was loaded with the contrast agent Galbumin as a control. Proper intraocular device placement was verified by magnetic resonance imaging (MRI) and clinical examination.

[0054] One week after implantation the rabbits were sacrificed and the eyes were removed for analysis. The concentration of Avastin in the retina and vitreous was detected by ELISA to be 24-48mcg / mL, and Avastin was present in the eyes of control rabbits. Figure 4 The Avastin content of each eye area analyzed one week after implantation is shown.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides devices, systems, and methods for delivery of an active agent into the eye of a subject. In one aspect, for example, an ocular active agent delivery device (10) can include an active agent reservoir (14) disposed in an annular housing (12), the annular housing (12) being configured to fit inside of a lens capsule and at least partially encircling a line of sight of an intraocular lens within the lens capsule. The device (10) can further include a semipermeable membrane (16) operatively coupled to the active agent reservoir (14), where the semipermeable membrane (16) is configured to allow diffusion of an active agent from the active agent reservoir (14). Additionally, a valve (18) can be operatively coupled to the active agent reservoir (14), where the valve (18) is configured to allow filling of the active agent reservoir (14) with an active agent.

Description

technical field [0001] The present invention relates to systems, methods and devices for ophthalmic delivery of active agents to the eye of a subject. Accordingly, the present invention relates to the fields of chemistry, materials and polymer science, drug delivery, pharmacy and medicine - especially ophthalmology. Background technique [0002] Age-related macular degeneration and glaucoma are the two leading causes of blindness in the United States and around the world. Current glaucoma treatments generally require polypharmacy, where the subject is usually prescribed several topical agents that must be applied to the eye at varying frequencies, in some cases as many as 3 to 4 times per day. Subjects often have difficulty following these dosing regimens consistently, and many develop the need for surgical treatment with major complications, such as intraocular shunt or trabeculectomy. [0003] Subjects with macular degeneration typically require monthly intravitreal inje...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61F9/00A61K9/00
CPCA61F9/0017B33Y80/00A61P27/02A61P27/06A61P31/04A61P37/06
Inventor B·K·阿姆霸提B·K·加勒
Owner UNIV OF UTAH RES FOUND
Features
  • Generate Ideas
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com